<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02955368</url>
  </required_header>
  <id_info>
    <org_study_id>DP-CTR212-III-03</org_study_id>
    <nct_id>NCT02955368</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Efficacy and Safety of DP-R212</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Parallel-group Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R212 Fixed Dose Combination in Patients With Dyslipidemia and Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alvogen Korea</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alvogen Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine superiority of DP-R212 comparing to each
      monotherapy in patient with hypertension and primary hypercholesterolemia.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Canceled
  </why_stopped>
  <start_date type="Anticipated">February 2017</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change of LDL-Cholesterol</measure>
    <time_frame>0, 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of mean seated Systolic Blood Pressure</measure>
    <time_frame>0, 8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hypertension</condition>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>DP-R212 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DP-R212 + C1-R212 placebo + C2-R212 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C1-R212 group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DP-R212 placebo + C1-R212 + C2-R212 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C2-R212 group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DP-R212 placebo + C1-R212 placebo + C2-R212</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DP-R212</intervention_name>
    <description>DP-R212 + C1-R212 placebo + C2-R212 placebo</description>
    <arm_group_label>DP-R212 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C1-R212</intervention_name>
    <description>DP-R212 placebo + C1-R212 + C2-R212 placebo</description>
    <arm_group_label>C1-R212 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C2-R212</intervention_name>
    <description>DP-R212 placebo + C1-R212 placebo + C2-R212</description>
    <arm_group_label>C2-R212 group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Both man and woman who is over 19 years old

          -  Hypertension patient with hypercholesterolemia

        Exclusion Criteria:

          -  sSBP difference is ≥20mmHg or sDBP difference is ≥10mmHg

          -  A history of cardiovascular disease

          -  rhabdomyolysis, myopathy

          -  Hypertension or hypercholesterolemia due to secondary causes

          -  Uncontrolled diabetes

          -  Evidence of hepatic or renal disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2016</study_first_submitted>
  <study_first_submitted_qc>November 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2016</study_first_posted>
  <last_update_submitted>June 1, 2017</last_update_submitted>
  <last_update_submitted_qc>June 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DP-R212</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Complement C1r</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

